| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
GeoVax Labs, Inc. (NASDAQ:GOVX) shares are trading higher Thursday on continued momentum from last week.
What To Know: GeoVax Labs received a BARDA Project NextGen award to conduct a study evaluating its COVID-19 vaccine candidate GEO-CM04S1.
According to Yahoo Finance, GeoVax will sponsor a Phase 2b study, containing 10,000 participants, to compare the efficacy and safety of GeoVax’s novel vaccine to a already FDA approved mRNA COVID-19 vaccine.
The monetary award to GeoVax, which will support necessary preparations for the clinical trial, is about $24.3 million. The award may increase later to a maximum of $45 million.
BARDA will fund the execution of the clinical trial separately. The funding for the execution is approximately $343 million.
How To Buy GeoVax Labs Stock
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Geovax Labs (NASDAQ:GOVX)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: Elanco Animal Health Shares Sink On Unexpected Label Update For Canine Dermatology Drug
GOVX Price Action: At the time of writing, GeoVax Labs stock is moving 102% higher at $4.08, according to data from Benzinga Pro.
Image: Photo via Pixabay
Posted In: GOVX
